ClinicalTrials.gov now labels NCT06223568, an NCI-sponsored head-and-neck cancer study, Recruiting. ENT Daily Dispatch’s October 16, 2026 selected-field read confirms that label. A retained observation from October 15 had listed Active, not recruiting.
This is a revision to an existing record. The study was first publicly posted on January 25, 2024. The latest revision was submitted on October 15, 2026 and posted on October 16; those dates do not establish when recruitment activity changed in practice.
The registered title describes neoadjuvant chemotherapy alone or combined with PRGN-2009 for newly diagnosed HPV-associated oropharyngeal cancer. National Cancer Institute (NCI) is the listed lead sponsor. These fields describe the registered research question and sponsor, without establishing a treatment result.
The selected U.S. location remains National Institutes of Health Clinical Center in Bethesda, Maryland. That entry is unchanged between the retained October 15 observation and the fresh read. The overall record’s Recruiting label does not independently verify that location’s current enrollment capacity or the number of participants enrolled.
Source: ClinicalTrials.gov, U.S. National Library of Medicine, NCT06223568. Metadata was retrieved October 16, 2026 UTC. The earlier complete collection reported processing token 2026-10-16T09:00:05, without a time-zone offset; that token is not an atomic version check of the later individual-record response. Fields were selected and normalized; U.S. location rows were retained, sorted and deduplicated. No contact, protocol or results fields were collected. No NLM or U.S. Government endorsement is implied.
The dated revision gives head-and-neck researchers a specific record to monitor while leaving actual site availability and clinical findings as separate verification questions.
Go to the source.
ClinicalTrials.gov · NCT06223568 ↗This brief summarizes publicly announced information. It does not establish clinical superiority or recommend a treatment.
